Carlsmed, Inc. (NASDAQ: CARL)

Carlsmed Inc is a commercial stage medical technology company that pioneers AI enabled personalized spine surgery solutions with a focus on becoming the standard of care for spine fusion surgery. The company’s core offering is the aprevo Technology Platform which delivers customized digital surgical plans and patient specific interbody implants designed to match each patient’s unique anatomy. The platform serves the lumbar and cervical spine fusion markets within the broader medical device industry.

Carlsmed generates revenue by selling the aprevo Technology Platform to hospitals and ambulatory surgical centers through a combination of a direct sales force and independent sales agents. Revenue is derived from the sale of patient specific aprevo interbody implants accompanying single use surgical instruments and access to the associated software and data analytics. The company’s customers are primarily healthcare providers that perform lumbar and cervical fusion procedures.

Carlsmed occupies a differentiated position in the spine fusion market as the first company to offer a fully integrated AI enabled platform that provides personalized surgical plans and patient specific implants. Its main competitors include established orthopedic device manufacturers such as Medtronic Johnson Johnson Globus Medical Orthofix and Alphatec. The company’s competitive advantages stem from a growing patent portfolio extensive clinical evidence demonstrating improved alignment and lower revision rates and favorable reimbursement policies that provide additional payments for use of its custom devices.

Carlsmed serves hospitals and ambulatory surgical centers that perform lumbar and cervical spine fusion procedures. The company’s customers range from large academic medical centers to community hospitals and outpatient surgery centers across the United States.